S100A9 promotes prostate cancer cell invasion by activating TLR4/NF-κB/integrin β1/FAK signaling.

FAK S100A9 integrin β1 metastasis prostate cancer

Journal

OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322

Informations de publication

Date de publication:
2020
Historique:
received: 25 10 2018
accepted: 16 04 2019
entrez: 5 9 2020
pubmed: 5 9 2020
medline: 5 9 2020
Statut: epublish

Résumé

S100A9, which is expressed in prostate cancer, has been reported in association with prostate cancer progression. However, the role of S100A9 in prostate cancer metastasis is largely unknown. The aim of this study was to investigate the effect of S100A9 on prostate cancer cell invasion and the involved mechanisms. Integrin β1 expression in PC-3 and DU-145 cells was determined by quantitative real-time polymerase chain reaction (PCR) (qRT-PCR) and Western blot. Cellular invasion was measured by transwell invasion assay. Western blot was used to determine protein expression. Concentrations of S100A9 and fibronectin were analyzed by enzyme-linked immunosorbent assay. The protein interaction was detected by immunoprecipitation. The NF-κB activity was measured by luciferase reporter assay. The DU-145 cells metastasis in vivo was determined in mice xenograft models after S100A9 overexpression. S100A9 promoted prostate cancer cells invasion, integrin β1 expression and fibronectin secretion. Further investigation evidenced that S100A9 interacted with Toll-like receptor 4 (TLR4) and activated NF-κB, which was responsible for tumor cell invasion, integrin β1 up-regulation and focal adhesion kinase (FAK) phosphorylation. Furthermore, integrin β1 inhibition led to decreased FAK phosphorylation and reduced tumor cell invasion. Overexpression of S100A9 increased xenograft tumor micro-metastases, integrin β1 expression and induced NF-κB and FAK activation in vivo. Our study demonstrated that S100A9 promotes prostate cancer cell invasion, and one of the underlying molecular mechanisms is that S100A9 activates integrin β1/FAK through TLR4/NF-κB signaling leading to metastasis of prostate cancer cell.

Sections du résumé

BACKGROUND BACKGROUND
S100A9, which is expressed in prostate cancer, has been reported in association with prostate cancer progression. However, the role of S100A9 in prostate cancer metastasis is largely unknown. The aim of this study was to investigate the effect of S100A9 on prostate cancer cell invasion and the involved mechanisms.
MATERIALS AND METHODS METHODS
Integrin β1 expression in PC-3 and DU-145 cells was determined by quantitative real-time polymerase chain reaction (PCR) (qRT-PCR) and Western blot. Cellular invasion was measured by transwell invasion assay. Western blot was used to determine protein expression. Concentrations of S100A9 and fibronectin were analyzed by enzyme-linked immunosorbent assay. The protein interaction was detected by immunoprecipitation. The NF-κB activity was measured by luciferase reporter assay. The DU-145 cells metastasis in vivo was determined in mice xenograft models after S100A9 overexpression.
RESULTS RESULTS
S100A9 promoted prostate cancer cells invasion, integrin β1 expression and fibronectin secretion. Further investigation evidenced that S100A9 interacted with Toll-like receptor 4 (TLR4) and activated NF-κB, which was responsible for tumor cell invasion, integrin β1 up-regulation and focal adhesion kinase (FAK) phosphorylation. Furthermore, integrin β1 inhibition led to decreased FAK phosphorylation and reduced tumor cell invasion. Overexpression of S100A9 increased xenograft tumor micro-metastases, integrin β1 expression and induced NF-κB and FAK activation in vivo.
CONCLUSION CONCLUSIONS
Our study demonstrated that S100A9 promotes prostate cancer cell invasion, and one of the underlying molecular mechanisms is that S100A9 activates integrin β1/FAK through TLR4/NF-κB signaling leading to metastasis of prostate cancer cell.

Identifiants

pubmed: 32884282
doi: 10.2147/OTT.S192250
pii: 192250
pmc: PMC7435298
doi:

Types de publication

Journal Article

Langues

eng

Pagination

6443-6452

Informations de copyright

© 2020 Lv et al.

Déclaration de conflit d'intérêts

The authors declare no competing financial interests in this work.

Références

Mol Cancer Res. 2013 Apr;11(4):405-17
pubmed: 23339185
Clin Exp Metastasis. 2013 Jun;30(5):569-78
pubmed: 23242739
Clin Cancer Res. 2005 Jul 15;11(14):5146-52
pubmed: 16033829
Mol Cancer Res. 2008 Oct;6(10):1544-53
pubmed: 18922970
Nat Med. 2010 Jun;16(6):713-7
pubmed: 20473308
Eur J Pharmacol. 2009 Dec 25;625(1-3):73-83
pubmed: 19835859
PLoS One. 2013 Apr 26;8(4):e62092
pubmed: 23637971
Int J Cancer. 2012 Dec 15;131(12):2785-94
pubmed: 22505354
Int J Cancer. 2017 Sep 1;141(5):998-1010
pubmed: 28542982
J Cell Sci. 2011 Feb 1;124(Pt 3):369-83
pubmed: 21224397
Cell Adh Migr. 2017 Jul 4;11(4):305-315
pubmed: 27715399
J Cell Physiol. 2014 May;229(5):661-71
pubmed: 24122301
Int J Oncol. 2013 Mar;42(3):1001-10
pubmed: 23354417
Arch Pathol Lab Med. 2008 Jun;132(6):931-9
pubmed: 18517275
Exp Cell Res. 2006 Jan 15;312(2):184-97
pubmed: 16297907
Cell Biol Int. 2012 Oct 1;36(10):883-92
pubmed: 22686483
Biochem Biophys Res Commun. 2016 Nov 25;480(4):522-527
pubmed: 27769864
Mol Cancer Res. 2011 Feb;9(2):133-48
pubmed: 21228116
Science. 1999 Aug 13;285(5430):1028-32
pubmed: 10446041
Cell Signal. 2014 May;26(5):1011-20
pubmed: 24486402
Nat Med. 2007 Sep;13(9):1042-9
pubmed: 17767165
Cancer Lett. 2014 Apr 1;345(1):91-9
pubmed: 24333724
J Exp Med. 2008 Feb 18;205(2):275-85
pubmed: 18208974
Nat Rev Cancer. 2014 Sep;14(9):598-610
pubmed: 25098269
Biochem Pharmacol. 2006 Nov 30;72(11):1622-31
pubmed: 16846592
J Clin Invest. 2018 Aug 1;128(8):3280-3297
pubmed: 29763414
Oncogene. 2015 Apr 2;34(14):1811-21
pubmed: 24793790
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Eur J Cancer. 2014 Jul;50(10):1829-1835
pubmed: 24726733
Nat Cell Biol. 2006 Dec;8(12):1369-75
pubmed: 17128264
Nat Cell Biol. 2008 Nov;10(11):1349-55
pubmed: 18820689
J Leukoc Biol. 2008 Jun;83(6):1484-92
pubmed: 18339893
Onco Targets Ther. 2018 Mar 12;11:1333-1343
pubmed: 29559792
Nat Commun. 2015 Apr 20;6:6915
pubmed: 25892652
J Biol Chem. 2010 Apr 2;285(14):10822-31
pubmed: 20118237
Cancer Lett. 2017 Jan 28;385:28-38
pubmed: 27832972

Auteurs

Zhonghua Lv (Z)

Department of Urology, Jining First People's Hospital, Jining, Shandong 272011, People's Republic of China.

Wenlin Li (W)

Department of Urology, Rizhao Traditional Chinese Medicine Hospital, Rizhao, Shandong 276800, People's Republic of China.

Xichao Wei (X)

Department of Urology, Jining Traditional Chinese Medicine Hospital, Jining, Shandong 272000, People's Republic of China.

Classifications MeSH